MARKET

MLYS

MLYS

Mineralys Therapeutics, Inc.
NASDAQ
26.68
+0.34
+1.29%
After Hours: 26.68 0 0.00% 17:25 06/26 EDT
OPEN
25.91
PREV CLOSE
26.34
HIGH
26.78
LOW
25.44
VOLUME
5.20M
TURNOVER
--
52 WEEK HIGH
47.65
52 WEEK LOW
12.59
MARKET CAP
2.35B
P/E (TTM)
-12.9754
1D
5D
1M
3M
1Y
5Y
1D
Mineralys Therapeutics (MLYS) Is Up 6.8% After New Lorundrostat Heart Failure Biomarker Data - What's Changed
Simply Wall St · 4d ago
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision
The Motley Fool · 4d ago
Weekly Report: what happened at MLYS last week (0615-0619)?
Weekly Report · 6d ago
Mineralys Therapeutics (MLYS) Stock Could Be 52% Undervalued After Funding Deal And Lorundrostat Data
Simply Wall St · 6d ago
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor
Seeking Alpha · 06/18 02:58
Mineralys Therapeutics director Daphne Karydas sells 3,000 shares valued at $75,000
PUBT · 06/18 01:18
Weekly Report: what happened at MLYS last week (0608-0612)?
Weekly Report · 06/15 09:36
Mineralys Reports Lorundrostat Reduced Heart Failure Risk Biomarkers In Hypertension Trials
NASDAQ · 06/15 09:26
More
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.

Webull offers Mineralys Therapeutics Inc stock information, including NASDAQ: MLYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLYS stock methods without spending real money on the virtual paper trading platform.